Youchun Wang

This paper develops FutureFlu, a framework to predict influenza vaccine strains by quantifying viral fitness, showing improved accuracy compared to current methods.

This paper predicts SARS-CoV-2 RBD evolution using deep mutational scanning to identify broadly neutralizing antibodies effective against existing and prospective variants.

This study evaluates novel prodrugs based on (S)-HPMPA and (S)-HPMPC, finding that ODE-(S)-HPMPA formate is more potent against orthopoxviruses and adenoviruses than BCV, but less effective against HSV-1.

This study analyzes the humoral immune response to SARS-CoV-2 XBB and JN.1 lineages, showing JN.1 elicits superior neutralization and highlights the need for JN.1-based vaccine boosters.

The paper investigates how Omicron-specific naive B cell maturation after breakthrough infection alleviates immune imprinting from inactivated SARS-CoV-2 vaccines.

This study identifies ultra-potent Omicron-specific antibodies targeting the N1/N2 loop of the Spike NTD, which neutralize SARS-CoV-2 by competing with ACE2 and blocking S1 shedding, but are evaded by BA.2.86 and BA.2.87.1 sublineages.

This study investigates how N354 glycosylation in the SARS-CoV-2 spike protein affects viral fitness and human adaptation through multiple mechanisms.

This study assesses the antigenic properties and immune evasion of the SARS-CoV-2 variant BA.2.87.1, finding it less resistant to neutralizing antibodies than JN.1 but with compensatory deletions in the NTD.

This study shows that convergent evolution of SARS-CoV-2 XBB lineages at RBD positions 455-456 synergistically enhances antibody evasion and ACE2 binding through epistatic interactions.

The paper shows JN.1 outcompetes BA.2.86 and other variants by evading antibodies more effectively, despite reduced ACE2 binding.

This study identifies a novel human antibody, AF-03, that targets MARV glycoprotein and shows neutralizing activity against MARV and related filoviruses.

This study characterizes the antigenic properties and infectivity of the SARS-CoV-2 BA.2.86 variant, finding it evades immune responses but has reduced infectivity compared to previous variants.